v3.26.1
Segment Disclosures (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Significant Expense
The table below summarizes the significant expense categories regularly reviewed by the CODM for the three and six months ended June 30:
Three Months Ended June 30,
20262025
Operating expenses:
Clinical product candidates$17,433 $17,710 
Pre-clinical product candidates504 231 
Employee costs- research and development3,814 2,594 
Employee costs-general and administrative2,451 2,083 
Non-cash stock compensation6,782 1,899 
Depreciation expense34 43 
Professional fees and other segment expenses4,309 2,523 
Total operating expenses35,327 27,083 
Loss from operations(35,327)(27,083)
Interest income1,286 241 
Other income (expense)(58)22 
Net loss$(34,099)$(26,820)
Six Months Ended June 30,
20262025
Operating expenses:
Clinical product candidates$38,354 $35,491 
Pre-clinical product candidates923 345 
Employee costs- research and development6,372 4,761 
Employee costs-general and administrative4,260 3,643 
Non-cash stock compensation11,248 3,941 
Depreciation expense67 86 
Professional fees and other segment expenses7,338 5,641 
Total operating expenses68,562 53,908 
Loss from operations(68,562)(53,908)
Interest income2,046 424 
Other income (expense)(171)1,191 
Net loss$(66,687)$(52,293)